Medtronic PLC $MDT Shares Purchased by Linscomb Wealth Inc.

Linscomb Wealth Inc. lifted its stake in Medtronic PLC (NYSE:MDT) by 2.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,305 shares of the medical technology company’s stock after purchasing an additional 1,825 shares during the period. Linscomb Wealth Inc.’s holdings in Medtronic were worth $7,087,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares in the last quarter. Clear Creek Financial Management LLC increased its holdings in Medtronic by 26.1% during the 1st quarter. Clear Creek Financial Management LLC now owns 4,535 shares of the medical technology company’s stock valued at $408,000 after acquiring an additional 940 shares in the last quarter. Rossby Financial LCC purchased a new position in Medtronic during the 1st quarter valued at about $160,000. Keybank National Association OH increased its holdings in Medtronic by 1.7% during the 1st quarter. Keybank National Association OH now owns 135,610 shares of the medical technology company’s stock valued at $12,186,000 after acquiring an additional 2,316 shares in the last quarter. Finally, Aaron Wealth Advisors LLC increased its holdings in Medtronic by 12.6% during the 1st quarter. Aaron Wealth Advisors LLC now owns 7,743 shares of the medical technology company’s stock valued at $696,000 after acquiring an additional 865 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE MDT opened at $90.88 on Friday. The business’s 50-day moving average price is $94.38 and its 200 day moving average price is $89.62. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $99.37. The company has a market capitalization of $116.57 billion, a PE ratio of 25.04, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same period in the prior year, the business posted $1.23 earnings per share. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is currently 78.24%.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Jellison bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their position. The SEC filing for this purchase provides additional information. 0.26% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Evercore ISI raised their target price on shares of Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. UBS Group raised their target price on shares of Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 20th. Morgan Stanley restated an “overweight” rating and set a $107.00 target price (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. Mizuho raised their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Finally, William Blair raised shares of Medtronic to a “hold” rating in a research note on Friday, July 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average price target of $102.82.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.